In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Takeda pays up to $140mm for Envoy Therapeutics

Executive Summary

Takeda Pharmaceutical Co. Ltd. and its Takeda America Holdings Inc. unit have agreed to pay up to $140mm to acquire privately held drug developer Envoy Therapeutics Inc. The deal value consists of an undisclosed up-front cash payment and progress-dependent earn-outs for preclinical projects. (Strategic Transactions will assume 25% of the $140mm is up front--$35mm--and the rest in earn-outs.)
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Includes Earnout
    • Partial Acquisition
    • Payment Includes Cash

Related Companies